Bristol-Myers Squibb makes upfront payment to Hengrui for drug assets
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Bristol-Myers Squibb paid Hengrui an upfront payment for 13 early-stage assets. During the same period, Bristol-Myers Squibb reported third-quarter revenue of $13.069 billion, which represented a 7% increase.
From finchannel.com
Why it matters
The transaction between Bristol-Myers Squibb and Hengrui relates to strategic drug program development. While Bristol-Myers Squibb's revenue grew, adjusted earnings were lowered by research and licensing charges, including a net negative impact of 58 cents a share in the third quarter.
From finchannel.com
Who's involved
- Bristol-Myers SquibbAmerican pharmaceutical company that paid the upfront payment and reported Q3 earnings
- HengruiCompany that received the upfront payment for early-stage assets
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Bristol-Myers SquibbSpeculative
Bristol-Myers Squibb might see increased revenue from the acquisition of early-stage assets.